NANOSONICS LIMITED (NAN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NAN - NANOSONICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.43
Index: ASX200 | ASX300 | ALL-ORDS

Nanosonics is an Australian medical device company manufacturing high level disinfection systems to reduce the spread of infection. Founded in 2001, the company listed on the ASX in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.87

16 Apr
2024

-0.110

OPEN

$2.94

-3.69%

HIGH

$2.98

1,190,312

LOW

$2.81

TARGET
$3.30 15.0% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
NAN: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A 2.5 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 111.3 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx6.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx167.5 M
Book Value Per Share xxxxxxxxxxxxxxx54.2
Net Operating Cash Flow xxxxxxxxxxxxxxx23.3 M
Net Profit Margin xxxxxxxxxxxxxxx11.87 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx13.14 %
Return on Invested Capital xxxxxxxxxxxxxxx12.44 %
Return on Assets xxxxxxxxxxxxxxx9.47 %
Return on Equity xxxxxxxxxxxxxxx13.14 %
Return on Total Capital xxxxxxxxxxxxxxx11.08 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx19.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx8 M
Total Debt xxxxxxxxxxxxxxx11 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx112 M
Price To Book Value xxxxxxxxxxxxxxx8.75

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx3.6 M
Capex % of Sales xxxxxxxxxxxxxxx2.13 %
Cost of Goods Sold xxxxxxxxxxxxxxx42 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx108 M
Research & Development xxxxxxxxxxxxxxx27 M
Investments - Total xxxxxxxxxxxxxxx1 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.1

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

27/02/2024

2

Accumulate

$4.00

39.37%

Ord Minnett trims FY24 revenue and EBIT forecast by -5% and -53%, respectively, after the first half results from Nanosonics. Budget constraints at hospitals provided a material hit to earnings with new global Trophon unit sales down -13% and replacement sales down -23%.

The broker still forecasts the North American installed base to grow by 5% per year to around 37,000 by 2028 before slowing as the market matures. First launches of Coris will be in Australia and Europe in FY25. Accumulate and $4 target maintained.

FORECAST
Ord Minnett forecasts a full year FY24 dividend of 0.00 cents and EPS of 2.00 cents.
Ord Minnett forecasts a full year FY25 dividend of 0.00 cents and EPS of 8.20 cents.

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

NAN STOCK CHART